秦都区复读学校正规联系电话(渭南高考补习哪里有效果好) (今日更新中)

WASHINGTON, Aug. 12 (Xinhua) -- NASA announced Friday the creation of a new directorate that will focus on both the International Space Station operations and human exploration beyond low earth orbit.The Human Exploration and Operations Mission Directorate combines the Space Operations and Exploration Systems mission directorates. While the transition and personnel assignments will take several weeks to finalize, the directorate already is supporting space station operations. It also will manage commercial crew and cargo developmental programs; construction of the Orion Multipurpose Crew Vehicle, a spacecraft designed to travel beyond low Earth orbit; development of a new heavy lift rocket, known as the Space Launch System; and other programs within the directorates."America is opening a bold new chapter in human space exploration," NASA Administrator Charles Bolden said in a statement. "By combining the resources of Space Operations and Exploration Systems, and creating the Human Exploration and Operations Mission Directorate, we are recommitting ourselves to American leadership in space for years to come."Associate Administrator Bill Gerstenmaier will head the new organization. He previously served as the associate administrator for Space Operations.

Robots perform a dance in a competition in Mudanjiang, northeast China's Heilongjiang Province, July 24, 2011. A nationwide robot competition was kicked off in the city on Sunday, with participants from 50 colleges and universities

BEIJING, Sept. 6 (Xinhuanet) -- A short-term memory loss may suggest the Alzheimer's disease, according to a new study made by Spanish researchers.The finding was published on Monday, in Archives of General Psychiatry, an American Medical Association journal.The researchers gathered data of 116 people with mild cognitive impairment (MCI) who developed Alzheimer's disease within two years, 204 patients with the condition who didn't develop Alzheimer's and 197 people with no cognitive problems.Mild cognitive impairment is usually marked by difficulties with short-term memory, such as losing your train of thought repeatedly or having trouble remembering what you did yesterday, according to the study.After assessing them by biomarker tests and cognitive measures, the researcher found the cognitive markers can forecast the variance."Remarkably, they accounted for nearly 50% of the predictive variance," said Dr. Gomar of Centro de Investigation Biomedica en Red de Salud Mental, Barcelona, who led the research.Mild cognitive impairment at the start of the study was a stronger predictor of Alzheimer's than most biomarkers, the researchers concluded.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.

MOSCOW, June 27 (Xinhua) -- Russia successfully launched a Cosmos class military satellite on Monday, said spokesman of the Russian Space Forces Alexei Zolotukhin.A Soyuz-U carrier rocket carrying the military satellite blasted off from the Plesetsk Plesetsk space center in northern Russia at 20:00 Moscow time (1600 GMT), Zolotukhin said."The rocket put the Cosmos series military satellite into the designated orbit at 20:08 Moscow time (1608 GMT)," he added.The spokesman also said the launch of the Soyuz-U carrier rocket "was the first time for this type of rockets" in this year.The launch carried out by a team from the Russian Space Forces was supervised by Space Forces Commander Oleg Ostapenko.The satellite, Cosmos-2472, is a new member to a Russian network of about 60-70 military reconnaissance satellites.

来源：资阳报